Trials / Completed
CompletedNCT03294135
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine. This study will further investigate the booster response in subjects who will receive their second booster dose\* in this study. \* Any booster given in this study will be the second that the subject has received (with regard to the follow-up of the previous study).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Encepur Adults | One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid. |
Timeline
- Start date
- 2017-10-05
- Primary completion
- 2021-10-25
- Completion
- 2021-10-25
- First posted
- 2017-09-26
- Last updated
- 2024-03-28
- Results posted
- 2024-03-28
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT03294135. Inclusion in this directory is not an endorsement.